Marktanalyse - Pressure Ulcers - Pipeline Review, H1 2017

Global Markets Direct
03.2017
37 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Pressure Ulcers - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pressure Ulcers — Pipeline Review, H1 2017, provides an overview of the Pressure Ulcers (Dermatology) pipeline landscape.

Pressure ulcers are an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pressure Ulcers — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pressure Ulcers (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pressure Ulcers (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pressure Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 3 and 5 respectively.

Pressure Ulcers (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pressure Ulcers (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Pressure Ulcers (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pressure Ulcers (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pressure Ulcers (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pressure Ulcers (Dermatology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pressure Ulcers (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pressure Ulcers (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pressure Ulcers - Overview

Pressure Ulcers - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pressure Ulcers - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pressure Ulcers - Companies Involved in Therapeutics Development

EyeGene Inc

Izun Pharmaceuticals Corp

MediWound Ltd

NovaLead Pharma Pvt Ltd

RegeneRx Biopharmaceuticals Inc

RMB-Research GmbH

Pressure Ulcers - Drug Profiles

AG-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-Decorin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EscharEx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IZN-6D4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLP-328 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGN-137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Statmicoll - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Pressure Ulcers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pressure Ulcers - Dormant Projects

Pressure Ulcers - Discontinued Products

Pressure Ulcers - Product Development Milestones

Featured News & Press Releases

Aug 24, 2016: MediWound's EscharEx to be Featured at International Society for Burn Injuries 2016

Dec 04, 2015: RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment

Jan 09, 2009: RegeneRx Reports Phase II Pressure Ulcer Trial Results

Sep 22, 2008: RegeneRx/Sigma-Tau Completes Patient Enrollment Of Second Phase II Clinical Trial With RGN-137

Aug 20, 2008: RegeneRx Completes Patient Enrollment Of First Phase II Clinical Trial

Nov 02, 2004: RegeneRx Gets Cleared To Initiate Phase II Clinical Trial With Tß4 For Chronic Pressure Ulcers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





List of Tables

Number of Products under Development for Pressure Ulcers, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pressure Ulcers - Pipeline by EyeGene Inc, H1 2017

Pressure Ulcers - Pipeline by Izun Pharmaceuticals Corp, H1 2017

Pressure Ulcers - Pipeline by MediWound Ltd, H1 2017

Pressure Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017

Pressure Ulcers - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017

Pressure Ulcers - Pipeline by RMB-Research GmbH, H1 2017

Pressure Ulcers - Dormant Projects, H1 2017

Pressure Ulcers - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Pressure Ulcers, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus